Sodium-glucose cotransporter 2 inhibitor Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through pAMPK, MyD88 and NLRP-3 pathways
Anno:
2025
Background: Combining anthracyclines and trastuzumab is highly effective in treating HER2-positive breast cancer but significantly increases the risk of cardiotoxicity. The sequential approach is often preferred, where anthracyclines are given first, followed by trastuzumab, with careful monitoring of heart function. Purpose: We report for the first time the cardioprotective…